Jun 2026 (Q2 FY26) — Aug 13, 2026
Sensus Healthcare Q2 FY26 — Delayed Revenue Recognition, Stronger H2 Outlook
Read the full callSensus Healthcare (SRTS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Sensus Healthcare earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2.3 | −68.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -138.9 | −112.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -8.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.76 −0.36% · −$0.01
Performance −13.8% 1Y
1Y: $3.2 on 17 Oct 2025 → $2.76. High $5.3 (13 Jan 2026), low $2.69 (8 Jun 2026).
- Previous close
- $2.77
- 52-week range
- $2.69 – $5.3
- One year
- −13.21%
Overview
- Symbol
- SRTS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Sensus Healthcare earnings calls (SRTS)
Financials
What the filings say
Net profit, year on year: −744% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 13 | 8 | 7 | 7 | 5 | 3 | 2 |
| Operating profit | 1 | 2 | -3 | -2 | -3 | -3 | -4 | -3 |
| Operating margin | 16.9% | 13.2% | −31.7% | −26.6% | −37.3% | −63.8% | −128.4% | −138.9% |
| Interest | — | — | -0 | -0 | — | — | — | — |
| Profit before tax | 2 | 2 | -2 | -2 | -2 | -3 | -4 | -3 |
| Tax rate | 31.5% | 21.0% | −4.5% | 41.1% | 60.9% | −5.8% | 38.0% | −185.6% |
| Net profit | 1 | 2 | -3 | -1 | -1 | -3 | -3 | -9 |
| EPS ($ per share) | 0.07 | — | -0.16 | -0.06 | -0.06 | — | -0.16 | -0.53 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -14 | -15 | -22 | -18 | 6 | 7 | 13 | 6 |
| Total liabilities | 7 | 9 | 7 | 6 | 9 | 5 | 6 | 5 |
| Fixed assets | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 2 |
| Total assets | 33 | 37 | 28 | 32 | 57 | 54 | 62 | 53 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -2 | -0 | -0 | -1 | -2 | -1 | 1 |
| Cash from investing | -3 | -5 | 7 | 0 | 15 | -0 | -0 | -0 |
| Cash from financing | 14 | 3 | 0 | -0 | -2 | -0 | 0 | -0 |
| Capital expenditure | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -9 | -3 | -1 | -0 | -2 | -2 | -1 | 0 |
Insider filings
18 filings between Nov 11, 2025 and Aug 31, 2026.
Open market
decisions to buy or sellPurchases
$728.0K
17 purchases by 3 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sachetta Eric | $554.4K | — | Aug 31, 2026 |
| Sardano Joseph C | $161.2K | — | Aug 20, 2026 |
| Sardano Michael | $12.3K | — | Nov 18, 2025 |
Latest filings (27)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Sachetta Eric Director | Purchase | 27,304 | $96.6K |
| Aug 28, 2026 | Sachetta Eric Director | Purchase | 37,537 | $129.0K |
| Aug 27, 2026 | Sachetta Eric Director | Purchase | 10,925 | $34.8K |
| Aug 26, 2026 | Sachetta Eric Director | Purchase | 9,708 | $31.9K |
| Aug 24, 2026 | Sachetta Eric Director | Purchase | 34,697 | $112.9K |
| Aug 21, 2026 | Sachetta Eric Director | Purchase | 7,000 | $22.8K |
| Aug 20, 2026 | Sachetta Eric Director | Purchase | 24,000 | $75.1K |
| Aug 20, 2026 | Sardano Joseph C CHIEF EXECUTIVE OFFICER | Purchase | 20,000 | $60.5K |
| May 12, 2026 | Sachetta Eric Director | Purchase | 1,500 | $5.0K |
| Feb 24, 2026 | Sachetta Eric Director | Purchase | 2,000 | $7.6K |
| Dec 12, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Award | 40,000 | $0 |
| Nov 21, 2025 | Sachetta Eric Director | Purchase | 7,000 | $27.5K |
| Nov 18, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 1,000 | $3.8K |
| Nov 18, 2025 | Sardano Joseph C CHIEF EXECUTIVE OFFICER | Purchase | 25,000 | $100.8K |
| Nov 13, 2025 | Sachetta Eric Director | Purchase | 2,500 | $11.3K |
| Nov 11, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 1,000 | $4.3K |
| Nov 11, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 766 | $3.3K |
| Nov 11, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 234 | $992 |
| Aug 13, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 1,000 | $3.4K |
| Feb 10, 2025 | Rampolla Javier CHIEF FINANCIAL OFFICER | Purchase | 501 | $3.0K |
| Feb 10, 2025 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Purchase | 1,000 | $6.0K |
| Dec 17, 2024 | Sardano Michael PRESIDENT AND GENERAL COUNSEL | Award | 40,000 | $0 |
| Dec 17, 2024 | Cornish Megan Director | Award | 20,000 | $0 |
| Dec 17, 2024 | McCall William H Director | Award | 20,000 | $0 |
| Dec 17, 2024 | Petrelli Anthony Benedict Director | Award | 20,000 | $0 |
| Dec 19, 2023 | Martinez Magdalena CHIEF OPERATING OFFICER | Tax withheld | 741 | $2.0K |
| Jul 21, 2022 | Rampolla Javier CHIEF FINANCIAL OFFICER | Tax withheld | 3,935 | $41.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Sensus Healthcare, Inc.
Free account. Everything above stays public.
Write why you follow Sensus Healthcare, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading